Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 38048793

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2024 Jan 6
First author
Oaknin A

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2024 Jan 6;403(10421):2-4. doi: 10.1016/S0140-6736(23)02690-9.
    note
    Source null
    related pmid
    38048788
    relationship
    Comment in

Authors and identifiers

  1. name
    Oaknin A
    type
    Author
  2. name
    Gladieff L
    type
    Author
  3. name
    Martínez-García J
    type
    Author
  4. name
    Villacampa G
    type
    Author
  5. name
    Takekuma M
    type
    Author
  6. name
    De Giorgi U
    type
    Author
  7. name
    Lindemann K
    type
    Author
  8. name
    Woelber L
    type
    Author
  9. name
    Colombo N
    type
    Author
  10. name
    Duska L
    type
    Author
  11. name
    Leary A
    type
    Author
  12. name
    Godoy-Ortiz A
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Oaknin A
    type
    Author
  2. name
    Gladieff L
    type
    Author
  3. name
    Martínez-García J
    type
    Author
  4. name
    Villacampa G
    type
    Author
  5. name
    Takekuma M
    type
    Author
  6. name
    De Giorgi U
    type
    Author
  7. name
    Lindemann K
    type
    Author
  8. name
    Woelber L
    type
    Author
  9. name
    Colombo N
    type
    Author
  10. name
    Duska L
    type
    Author
  11. name
    Leary A
    type
    Author
  12. name
    Godoy-Ortiz A
    type
    Author
bibliography ids
  1. nci-bib-8392ec7a8ff513cec7589211
book metadata
content sha256
b6133814dd28c281a1ebc0128588814a512d87b995a21b78897cbb2982d99dbc
document type
citation
dois
  1. 10.1016/S0140-6736(23)02405-4
electronic publication date
display
2023 Dec 1
precision
day
year
2023
evidence scope
bibliographic_metadata_only
id
pubmed:38048793
immutable id
pubmed:38048793@b6133814dd28c281a1ebc0128588814a512d87b995a21b78897cbb2982d99dbc
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10421
name
Lancet (London, England)
nlm unique id
2985213R
pages
31-43
volume
403
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2024 Jan 6;403(10421):2-4. doi: 10.1016/S0140-6736(23)02690-9.
    note
    Source null
    related pmid
    38048788
    relationship
    Comment in
outcomes validated
false
pmid
38048793
provenance
batch id
6d213eecf21b6b7867cb
provider
NCBI PubMed ESummary
record sha256
3851a7067faf52a2eae499c92a6a5d0c60c36d01ec6ab1563dfd9a02d1123dd3
response sha256
684f894a21d8f5f78a3bd0acd8ee4215ff94144487c53dab1056650ee8d6751d
retrieved at
2026-09-09T23:48:19.049083+00:00
publication date
display
2024 Jan 6
precision
day
year
2024
publication types
  1. Randomized Controlled Trial
  2. Clinical Trial, Phase III
  3. Journal Article
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/38048793/
title
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.

Preserved source evidence · Not medical advice